Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
53 hedge funds and large institutions have $896M invested in Generation Bio in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
54% more capital invested
Capital invested by funds: $581M → $896M (+$316M)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
10% more funds holding
Funds holding: 48 → 53 (+5)
2% more ownership
Funds ownership: 61.37% → 63.37% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.1M |
| 2 |
BlackRock
New York
|
+$15.6M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$10.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.94M |
| 5 |
Bank of New York Mellon
New York
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.7M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$11.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.83M |
| 4 |
Millennium Management
New York
|
-$5.51M |
| 5 |
DM
Deerfield Management
New York
|
-$5.38M |
GBIO Hedge Fund Activity: Q3 2020 in Review
53 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2020, worth a combined $896M — up 54% from $581M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GBIO positions and 18 closed out — a net gain of 5 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $19.1M. The largest seller was Citadel Advisors, cutting an estimated $12.7M.
- 53 institutional investors held Generation Bio (GBIO) as of Q3 2020, up from 48 in Q2 2020.
- Funds reported $896M of Generation Bio stock for Q3 2020, up 54% quarter-over-quarter.
- 23 funds opened new Generation Bio positions in Q3 2020 and 18 closed out, a net change of +5 holders.
- The largest Generation Bio buyer in Q3 2020 was Vanguard Group, an estimated $19.1M added.
- The largest Generation Bio seller in Q3 2020 was Citadel Advisors, an estimated $12.7M sold.
Based on aggregated 13F filings for Q3 2020.